中医药及GLP-1受体激动剂治疗2型糖尿病合并多囊卵巢综合征的研究进展

Research Advances in Traditional Chinese Medicine and GLP-1 Receptor Agonists for Treating Type 2 Diabetes with Polycystic Ovary Syndrome

摘要: 目的：探讨中医药复方及GLP-1受体激动剂治疗2型糖尿病(T2DM)合并多囊卵巢综合征(PCOS)研究进展，为该复杂共病寻找更安全、有效且个体化的治疗方案，同时明确两种疗法的作用机制、优势与不足，优化临床治疗。T2DM合并PCOS需同时改善血糖代谢、胰岛素抵抗及性激素水平，现有疗法效果常有限。研究旨在验证两种疗法能否针对性解决多靶点问题，提升整体治疗效果。明确作用机制与优势：通过研究明确中医药与GLP-1受体激动剂的具体作用路径，对比二者在疗效、安全性上的差异，为临床选择提供依据。探索两种疗法单独使用、联合使用的可行性与最优模式，为后续制定中西医结合或个体化治疗指南提供循证医学支持，填补该领域治疗方案的空白。

Abstract: Objective: Exploring the therapeutic advances of traditional Chinese medicine (TCM) compound formulas and GLP-1 receptor agonists in treating type 2 diabetes mellitus (T2DM) with polycystic ovary syndrome (PCOS), this study aims to identify safer, more effective, and personalized treatment strategies for this complex comorbidity. It also seeks to clarify the mechanisms of action, advantages, and limitations of both therapies to optimize clinical management. T2DM with PCOS requires simultaneous improvement in glucose metabolism, insulin resistance, and sex hormone levels, yet existing therapies often yield limited results. This study aims to validate whether these two therapies can specifically address multi-target issues and enhance overall treatment efficacy. Clarifying Mechanisms and Advantages: By elucidating the specific pathways of TCM and GLP-1 receptor agonists, and comparing their differences in efficacy and safety, this research provides evidence for clinical decision-making. Explore the feasibility and optimal patterns of using these therapies alone or in combination. This will provide evidence-based support for developing integrated Chinese-Western medicine or personalized treatment guidelines, filling a gap in therapeutic approaches within this field.